Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

OLANZAPINE IMPURITY A CRS (5 MG)

OLANZAPINE IMPURITY A CRS (5 MG)

138564-59-7

DISCOVER
LINCOMYCIN HYDROCHLORIDE FOR SYSTEM SUITABILITY CRS (10 MG)

LINCOMYCIN HYDROCHLORIDE FOR SYSTEM SUITABILITY CRS (10 MG)

7179-49-9

DISCOVER
FUSIDIC ACID FOR PEAK IDENTIFICATION CRS (15 MG)

FUSIDIC ACID FOR PEAK IDENTIFICATION CRS (15 MG)

03/06/6990

DISCOVER
VORICONAZOLE CRS (120 MG)

VORICONAZOLE CRS (120 MG)

137234-62-9

DISCOVER
VORICONAZOLE IMPURITY B CRS (15 MG)

VORICONAZOLE IMPURITY B CRS (15 MG)

NA

DISCOVER
VORICONAZOLE IMPURITY E CRS (60 MG)

VORICONAZOLE IMPURITY E CRS (60 MG)

02/08/5872

DISCOVER
VORICONAZOLE IMPURITY D CRS (10 MG)

VORICONAZOLE IMPURITY D CRS (10 MG)

NA

DISCOVER
FULVESTRANT CRS (130 MG)

FULVESTRANT CRS (130 MG)

129453-61-8

DISCOVER
VIGABATRIN CRS (10 MG)

VIGABATRIN CRS (10 MG)

60643-86-9

DISCOVER
VIGABATRIN IMPURITY A CRS (40MG)

VIGABATRIN IMPURITY A CRS (40MG)

NA

DISCOVER
VIGABATRIN IMPURITY B CRS (20MG)

VIGABATRIN IMPURITY B CRS (20MG)

NA

DISCOVER
VIGABATRIN IMPURITY E CRS (10MG)

VIGABATRIN IMPURITY E CRS (10MG)

NA

DISCOVER